Mode
Text Size
Log in / Sign up

Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinomaOne woman diagnosed with two different types of cancer simultaneously

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that immunohistochemical panels are essential to differentiate primary breast cancer from metastatic ovarian carcinoma.

This case report and literature review describes a 48-year-old premenopausal woman presenting with concurrent primary breast invasive carcinoma and metastatic high-grade serous ovarian carcinoma. The patient underwent neoadjuvant chemotherapy, surgery, and maintenance therapy with bevacizumab and fluzaparib.

The authors highlight the diagnostic challenge posed by morphologically similar adenocarcinoma components in patients with multiple malignancies. In this case, immunohistochemical profiling was necessary to confirm the coexistence of both primary breast and metastatic ovarian cancers. The patient achieved a partial response to neoadjuvant chemotherapy and showed no evidence of disease progression at the last follow-up.

A significant limitation of this report is its status as a single case study, which means the findings cannot be generalized to a broader population. However, it underscores the clinical importance of utilizing comprehensive immunohistochemical panels when diagnosing breast lesions in patients with known or suspected ovarian carcinoma to ensure accurate primary site identification.

How this fits prior evidence

This case highlights the diagnostic difficulty of identifying primary sites in complex presentations, similar to how signet ring morphology can mask metastatic breast cancer in gastric biopsies. While this report focuses on the necessity of immunohistochemical profiling for distinguishing between breast and ovarian components, it addresses a gap in clinical practice regarding the differentiation of morphologically distinct adenocarcinomas.

Imagine the shock of finding out that your body is fighting two different types of cancer at the same time. This is what happened to a 48-year-old woman who presented with symptoms like abdominal swelling and multiple breast nodules. Doctors eventually discovered she had both a primary breast cancer and metastatic ovarian cancer simultaneously.

Because these two cancers can look similar under a microscope, it is often hard for doctors to tell them apart. In this case, the medical team used special testing called immunohistochemical profiling to confirm that the tumors were actually coming from two different sources. This step was vital in identifying both conditions correctly.

While the patient showed a partial response to her initial chemotherapy and had no signs of disease progression at her last follow-up, it is important to remember this was a single case study. Because only one person was involved, these specific results cannot be applied to everyone with similar symptoms. It serves as a reminder for doctors to use detailed testing when they find unusual clusters of tumors.

What this means for you:
A rare case shows that breast and ovarian cancers can occur at once, making specialized testing vital for diagnosis.

Common questions

How did doctors tell the two cancers apart?

The doctors used immunohistochemical profiling. This is a special type of testing that looks at the proteins and markers in the cells. It allowed them to see that the breast nodules and the ovarian cancer were morphologically distinct, meaning they looked different under a microscope.

What treatments did the patient receive?

The patient received several types of treatment, including paclitaxel plus carboplatin, bevacizumab, and fluzaparib. These were used in different stages of her care, including before surgery and as a maintenance therapy.

Is this finding common for other patients?

Because this was a single case report involving only one patient, the results cannot be generalized to everyone. It is a rare occurrence that highlights why specific testing is important when doctors find complex symptoms.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundBreast metastasis from high-grade serous ovarian carcinoma is rare, and its coexistence with a synchronous primary breast carcinoma is exceptionally uncommon. Distinguishing metastatic ovarian carcinoma from primary breast carcinoma is clinically important because treatment strategies and prognosis differ substantially.Case presentationWe report a 48-year-old premenopausal woman who presented with pleural effusion, abdominal distension, bilateral adnexal masses, multiple breast nodules, and systemic lymphadenopathy. Pathological examination of the pelvic lesion supported high-grade serous carcinoma, whereas breast biopsy demonstrated two morphologically distinct adenocarcinoma components. Immunohistochemical profiling, including breast-lineage markers and Müllerian/ovarian markers, supported the coexistence of primary breast invasive carcinoma and metastatic ovarian carcinoma involving the breast.Intervention and outcomeThe patient was diagnosed with FIGO stage IVB high-grade serous ovarian carcinoma with breast, pleural, peritoneal, and lymph node involvement, synchronous with primary breast carcinoma. She received neoadjuvant paclitaxel plus carboplatin and achieved a partial response, followed by interval cytoreductive surgery, additional chemotherapy combined with bevacizumab, breast tumor excision, and maintenance therapy with fluzoparib plus bevacizumab. At the last follow-up on December 20, 2025, no evidence of disease progression was observed.ConclusionThis case highlights the diagnostic difficulty of breast lesions in patients with ovarian carcinoma. Morphology combined with an appropriate immunohistochemical panel is essential for distinguishing primary breast carcinoma from metastatic ovarian carcinoma. Multidisciplinary evaluation and genetic assessment should be considered in similar cases.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.